If you ask a family preparing for pregnancy:

“What is the most important supplement during preconception?”

Nine out of ten people would answer:

Folic acid.

But here comes the real question:

Is the folic acid you are taking actually being used by your body?

This question is becoming a new focus in global reproductive medicine, genetic nutrition, and perinatal medicine.

Especially for Chinese people and the entire Asian population, this may be even more important than for Western populations.

Because more and more studies have found that:

A considerable proportion of Asians carry MTHFR gene polymorphisms, which reduce the conversion efficiency of traditional folic acid (Folic Acid).

This is why, in recent years, a new concept has started to rise rapidly:

Active folate (L-5-MTHF / 5-Methyltetrahydrofolate)

It is reshaping the medical understanding of preconception, miscarriage prevention, fetal development, and even postpartum recovery.

1. Folic acid has been supplemented for decades—why do problems still remain?

In 1991, the prestigious British medical journal The Lancet published a groundbreaking study:

The MRC Vitamin Study Research Group confirmed that:

Supplementing folic acid can reduce the risk of neural tube defects (NTDs) by about 72%.

This study almost changed the global obstetric standard.

Afterward:

World Health Organization (WHO)

Centers for Disease Control and Prevention (CDC)

American College of Obstetricians and Gynecologists (ACOG)

all jointly recommended:

Taking 400μg of folic acid from at least one month before conception until the 12th week of pregnancy.

But decades later, reality remains harsh:

Around 300,000 babies worldwide are still born each year with neural tube defects.

Why?

The answer may be:

Not everyone can convert “regular folic acid” into the active form that the body truly needs.

2. Chinese and Asian populations may need to pay more attention to this issue

After folic acid enters the human body, it cannot work directly.

It must go through a key enzyme:

MTHFR (Methylenetetrahydrofolate Reductase)

This enzyme acts like a “converter.”

It is responsible for converting regular folic acid into:

5-MTHF (active folate)

Here comes the problem:

The mutation rate of MTHFR C677T is significantly higher in Asians.

According to Nature Publishing Group and multiple Asian cohort studies:

The TT genotype in some parts of China can reach 20%–30%.

For TT-type individuals:

The folic acid conversion efficiency may drop by 40%–70%.

This means:

Taking folic acid does not necessarily mean absorbing it effectively.

3. This may explain many “century-old mysteries”

In the past, medicine could not fully explain many problems:

1. Why do some people fail to conceive for a long time?

Active folate is involved in:

DNA replication

Egg maturation

Sperm production

Embryo implantation

Excessive homocysteine can damage the microcirculation of the endometrium.

Active folate can help lower it.

This directly affects:

Implantation rate

IVF success rate

Embryo quality

A study published in Fertility and Sterility pointed out:

Women with high homocysteine levels have a significantly higher miscarriage rate.

2. Why do recurrent miscarriages happen?

Many “unexplained miscarriages” were later found to be related to:

Abnormal folate metabolism

Coagulation disorders

MTHFR mutations

In the past, the only options were:

Miscarriage prevention injections, progesterone, and bed rest.

But these often treated the symptoms rather than the root cause.

Now:

More and more fertility centers have started using:

Active folate + Vitamin B6 + Vitamin B12 combined intervention

to improve methylation pathways.

This represents a new direction in precision nutrition therapy.

3. Why do some children develop slowly after birth?

Fetal nervous system development is highly dependent on methylation.

Active folate directly participates in:

Neural tube closure

Brain neuron differentiation

DNA methylation

Neurotransmitter production

Deficiency may increase the risk of:

Developmental delays

Autism spectrum disorders (under study)

Attention deficit disorders (under study)

These findings are still under observation and have not yet established final causality.

4. Is active folate a “new drug”?

Strictly speaking:

No, it is not a new drug.

It belongs to:

The next generation of folate supplementation technology

Its core ingredient is:

L-methylfolate calcium

Compared with traditional folic acid:

Traditional folic acid:

Advantages:

Affordable

Stable

Supported by a large amount of clinical data

Disadvantages:

Requires liver conversion

Depends on MTHFR

Poor utilization in some individuals

Active folate:

Advantages:

Can be absorbed directly

Does not require MTHFR conversion

Works faster

More suitable for people with genetic mutations

Disadvantages:

More expensive

Large-scale long-term RCTs are still insufficient

National guidelines have not fully replaced traditional folic acid

This point is very important:

As of 2026, WHO and CDC still list folic acid as the first-line recommendation.

Because it still has the strongest evidence for preventing neural tube defects.

5. New technology: genetic testing is bringing preconception into the precision era

In the past:

Everyone was told to take folic acid in the same way.

Now:

Test the genes first.

New technology:

MTHFR genetic testing

can quickly identify:

CC (normal)

CT (moderate risk)

TT (high risk)

This type of testing is already widely used in advanced fertility centers in:

China

Japan

South Korea

Singapore

United States

The future trend:

Genetic testing + personalized supplementation plans

This may become the next standard for preconception care.

6. An even bigger breakthrough: active folate is now being used in postpartum depression treatment

This is one of the most remarkable new directions in recent years.

Harvard-affiliated psychiatric research in the United States found that:

L-methylfolate can be used as an adjunctive treatment for depression.

Especially for:

People with poor folate metabolism.

This was published in the American Journal of Psychiatry.

Its significance is enormous:

Because postpartum depression has long been an unresolved global challenge.

In the future:

Taking active folate before pregnancy may not only help prevent miscarriage,

but may also protect the mother’s brain health.

This represents a new step forward in medicine.

7. How far can this evolve in the future?

The next 5–10 years may bring:

1. AI + Genetics + Nutrition Models

Input:

Genes

Hormones

Semen quality

AMH

Age

Automatically generating:

The best personalized preconception nutrition plan.

2. Smart wearable devices to monitor folate status

Real-time monitoring of:

Homocysteine

Vitamin B12

Folate metabolism efficiency

Dynamically adjusting supplementation dosage.

3. Personalized methylation therapy in IVF

For:

Repeated IVF failures

Advanced maternal age

Chromosomal abnormality risks

This may significantly improve live birth rates.

It is currently still in the clinical exploration stage.

The final question every family should think about:

If you knew that:

Your body might not even be able to convert regular folic acid.

Would you still continue to “randomly buy a bottle”?

Perhaps in the future, preconception care will no longer be about:

“Whether to take folic acid”

but rather:

“Whether you are taking the right type for your body.”

This is not marketing.

This is precision medicine changing the starting line of the next generation.

And Chinese families may need to face this issue earlier than anywhere else.

References and Sources (to avoid misinformation)

MRC Vitamin Study Research Group. Prevention of neural tube defects: The Lancet, 1991.

CDC Folic Acid Guidelines, 2025–2026.

WHO Periconceptional Folic Acid Supplementation, 2023.

Crider KS et al. Annual Review of Nutrition, 2022.

Nature Reviews Genetics – MTHFR polymorphism population distribution.

Fertility and Sterility – Hyperhomocysteinemia and miscarriage studies.

Papakostas GI et al. American Journal of Psychiatry, L-methylfolate adjunctive treatment.

NIH / NICHD Neural Tube Defects FAQ.